Reference 10 Part 2(ii)
Positron emission tomography [Part 2(ii)]
Positron emission tomography [Part 2(ii)]
Reference No. | 10 Part 2(ii) |
| Reference Name | Positron emission tomography [Part 2(ii)] |
| Advisory Panel | Dr Richard King (Chair and MSAC member) Professor Brendon Kearney (MSAC member) Dr Michael Kitchener (MSAC member) Mr Alan Keith (MSAC member) Dr John Primrose (Medical Adviser to the MSAC) Associate Professor Michael Fulham (Australian Associations of Neurologists nominee) Associate Professor Rodney Hicks (Australian and New Zealand Association of Physicians in Nuclear Medicine nominee) Associate Professor Ken Miles (Royal Australian and New Zealand College of Radiologists nominee) Dr Michael Millward (Royal Australian College of Physicians nominee) Associate Professor Andrew Scott (Australian and New Zealand Association of Physicians in Nuclear Medicine nominee) Professor Robert Thomas (Royal Australasian College of Surgeons nominee) |
| Date Received by MSAC Secretariat | September 2000 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 23 May 2001 meeting. The MSAC concludes that; - there is insufficient evidence at this time from which to draw definitive conclusions about the clinical effectiveness and cost-effectiveness of FDG PET; - for the indications of SCC of the head and neck and sarcoma, PET is used in addition to other diagnostic modalities; and - in terms of adverse patient reaction to administration of FDG, FDG PET is safe |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 18 September 2001 |
| Stage 5 - Implementation |  |
Page currency, Latest update: 30 March, 2009
